

REQUEST FOR ACCESS TO AN APPLICATION UNDER 37 CFR 1.14(e)

In re Application of _____

Application Number

09/256,388

Filed

2/24/99

Art Unit

Examiner

Paper No. #8

Assistant Commissioner for Patents
Washington, DC 20231

1. ☒ I hereby request access under 37 CFR 1.14(e)(2) to the application file record of the above-identified ABANDONED Application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and is: (CHECK ONE)

☐ (A) referred to in:

United States Patent Application Publication No. _____, page _____, line _____,

United States Patent Number 6177077 B1, column _____, line _____, or

an International Application which was filed on or after November 29, 2000 and which

designates the United States, WIPO Pub. No. _____, page _____, line _____.

☐ (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11(b) or

1.14(e)(2)(i), i.e., Application No. _____, paper No. _____, page _____, line _____.

2. ☐ I hereby request access under 37 CFR 1.14(e)(1) to an application in which the applicant has filed an authorization to lay open the complete application to the public.

Patricia A. Feltenz
Signature

4/30/02
Date

Patricia A Feltenz
Typed or printed name

FOR PTO USE ONLY

Approved by: DW

(initials)

Unit: ELN



US006177077B1

(12) **United States Patent**
Tobinick

(10) **Patent No.:** **US 6,177,077 B1**
(45) **Date of Patent:** ***Jan. 23, 2001**

(54) **TNT INHIBITORS FOR THE TREATMENT
OF NEUROLOGICAL DISORDERS**

(76) **Inventor:** **Edward L. Tobinick, 100 UCLA
Medical Plaza, Suite 205, Los Angeles,
CA (US) 90024-6903**

(*) **Notice:** Under 35 U.S.C. 154(b), the term of this
patent shall be extended for 0 days.

This patent is subject to a terminal dis-
claimer.

(21) **Appl. No.:** **09/476,643**

(22) **Filed:** **Dec. 31, 1999**

Related U.S. Application Data

(63) Continuation-in-part of application No. 09/275,070, filed on
Mar. 23, 1999, now Pat. No. 6,015,557, which is a continu-
ation-in-part of application No. 09/256,388, filed on Feb. 24,
1999, now abandoned.

(51) **Int. Cl.⁷** **A61K 39/395**

(52) **U.S. Cl.** **424/134.1**

(58) **Field of Search** **424/134.1**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,574,022 11/1996 Roberts et al. .
5,605,690 2/1997 Jacobs et al. .

5,650,396 7/1997 Carlino et al. .
5,656,271 8/1997 Le et al. .
5,756,482 5/1998 Roberts et al. .
5,962,481 * 10/1999 Levin et al. 514/352

* cited by examiner

Primary Examiner—William R. A. Jarvis

(74) *Attorney, Agent, or Firm*—Ezra Sutton

(57) **ABSTRACT**

A method is disclosed for inhibiting the action of TNF for
treating neurological conditions in a human by administer-
ing a TNF antagonist for reducing the inflammation of
neuronal tissue or the neuromuscular junction of a human, or
for modulating the immune response affecting neuronal
tissue or the neuromuscular junction of a human by admin-
istering to the human a therapeutically effective dosage level
of a TNF antagonist. The TNF antagonist is selected from
the group consisting of etanercept, infliximab, pegylated
soluble TNF receptor Type I (PEGsTNF-R1), other agents
containing soluble TNF receptors, CDP571 (a humanized
monoclonal anti-TNF-alpha antibody), other monoclonal
anti-TNF-alpha antibodies, TNF-alpha converting enzyme
inhibitors and D2E7 (a human anti-TNF mAb) for reducing
the inflammation of neuronal tissue or the neuromuscular
junction of a human, or for modulating the immune response
affecting neuronal tissue or the neuromuscular junction of a
human.

29 Claims, No Drawings